NSCLC

[Histology and Histopathology] Cell counting kit-8, flow cytometry and transwell assays were performed to determine the proliferation, apoptosis and invasion of NSCLC cells, respectively. In addition, western blotting was used to detect the levels of phosphorylated (p-)c-Raf, p-ERK and p-MEK in NSCLC cells.

[Archives of Pharmacal Research] Investigators showed that several NSCLC cell lines have differential sensitivity to NK cell–mediated cytotoxicity: NCI-H522 cells were highly sensitive, but A549, NCI-H23, NCI-H1915, and NCI-H1299 were resistant.

[Cullinan Oncology, Inc.] Cullinan Oncology, Inc. reported updated data from the Company’s ongoing Phase I/IIa trial of CLN-081 in non-small cell lung cancer patients whose tumors harbor epidermal growth factor receptor exon 20 insertion mutations that have progressed on or after prior therapy.

[Frontiers in Cell and Developmental Biology] Scientists found that halofuginone inhibited the proliferation, induced G0/G1 phase arrest, and promoted apoptosis in lung cancer cells in a dose-dependent manner.

[Communications Biology] Researchers presented a small-molecule compound D6 which selectively inhibited tumor cell growth and migration in NSCLC cells with EGFR-TKI-resistant T790M-EGFR-activated mutations.

[SOTIO Biotech] SOTIO Biotech announced that it has entered into a clinical trial collaboration and supply agreement with MSD to evaluate the combination of SOT101, SOTIO’s IL-15 superagonist, and MSD’s KEYTRUDA® in patients with selected advanced/refractory solid tumors in the Phase II AURELIO-04 study.